The application discloses a kind of polypeptides for treating Parkinson's
disease.In the application, it is first found that transient
receptor potential M2 type (TRPM2) channel is more expressed in fragile DA
neuron subgroup, and its expression amount is positively correlated with age in Parkinson's
disease (PD) patient, and the
mechanism of action is determined through rigorous experiment, i.e.TRPM2 channel is preferentially activated in ADE
neuron through PARP-1 / PARG / ADPR axis, drives Mfn2 / Bcl-2 complex dependent mitochondrial superfusion, causes ADE
neuron death.In addition, TRPM2 channel also drives
MPTP treatment mouse SNc DA neuron susceptibility through Mfn2 / Bcl-2 mediation.Firstly, it is found that blocking PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 mediated DA
neuron death pathway can prevent the death of
induced pluripotent stem cell (iPSC) derived DA neuron specific to spontaneous Parkinson's
disease (SPD) patient.As susceptible SNc DA
neuron loss is the main symptom of PD, therefore, PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 pathway can become a new therapeutic target for PD.